Dermavant Sciences: Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA (tapinarof) cream, 1% for Adults and Children as Young as 2 Years Old with Atopic Dermatitis at the 2023 EADV Congress finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children as Young as 2 Years Old with Atopic Dermatitis at the 2023 EADV Congress lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study
- Five posters will highlight clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients as young as two - Dermavant Sciences, a biopharmaceutical
- Two posters will highlight clinical data for VTAMA cream on treat-to-target outcomes and quality of life measures - Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing